Lallemand and Nimble begin capsule clinical trial

Published: 1-Feb-2021

The ingestible capsule passively samples the small intestine and autonomously transits the gastrointestinal tract

Lallemand Health Solutions and Nimble Science have begun a North American clinical study of Nimble’ small intestine microbiome aspiration (SIMBA) capsule, led by Dr Christopher N. Andrews of the Division of Gastroenterology at the University of Calgary.

“This particular capsule can be used to provide a novel solution for research of the gut microbiota, investigating various health conditions etiology, impact of interventions specifically within the small intestine and new biomarker identification, hence leading to advances in personalised medicine and nutrition. Lallemand Health Solutions is proud to support this innovative non-invasive technology to improve the understanding of probiotic intervention”, said Sara Caballero, Clinical Research Specialist at the Rosell Institute for Microbiome and probiotics, by Lallemand.

The study titled: “Use of the Small Intestine Microbiome Aspiration (SIMBA) Capsule to detect Dietary Intervention in the Small Intestine” will recruit 20 participants and is expected to be completed within the first quarter of 2021. The study is being conducted under investigational testing authorisation from Health Canada (#318739) and University of Calgary Conjoint Research Ethics Board (REB20-1211).

Nimble Science aims to develop a scalable, passive access to the gut microbiome to enable innovation for the detection and treatment of human disease. Throughout 2021 the company plans to collaborate with a range of partners.

You may also like